Universitair KinderZiekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
Arch Dis Child. 2014 Oct;99(10):933-6. doi: 10.1136/archdischild-2013-304727. Epub 2014 Jun 9.
Guidelines recommend extensively hydrolysed cow's milk protein formulas (eHF) in the treatment of infants diagnosed with cow's milk protein allergy (CMPA). Extensively hydrolysed rice protein infant formulas (eRHFs) have recently become available, and could offer a valid alternative.
A prospective trial was performed to evaluate the clinical tolerance of a new eRHF in infants with a confirmed CMPA. Patients were followed for 1 month. Clinical tolerance of the eRHF was evaluated with a symptom-based score (SBS) and growth (weight and length) was monitored.
Thirty-nine infants (mean age 3.4 months, range 0.5-6 months) diagnosed with CMPA were enrolled. All infants tolerated the eRHF and experienced a normal growth.
In accordance with current guidelines, this eRHF is tolerated by more than 90% of children with proven CMPA with a 95% CI, and is an adequate alternative to cow's milk-based eHF.
ClinicalTrials.gov NCT01998074.
指南推荐在治疗确诊为牛奶蛋白过敏（CMPA）的婴儿时广泛使用水解牛奶蛋白配方（eHF）。最近，可广泛水解的大米蛋白婴儿配方（eRHF）已经问世，并且可能是一种有效的替代选择。
进行了一项前瞻性试验，以评估一种新的 eRHF 在确诊为 CMPA 的婴儿中的临床耐受性。患者接受了 1 个月的随访。采用基于症状的评分（SBS）评估 eRHF 的临床耐受性，并监测生长（体重和身长）。
共纳入 39 名（平均年龄 3.4 个月，范围 0.5-6 个月）确诊为 CMPA 的婴儿。所有婴儿均耐受 eRHF，且生长正常。
根据现行指南，该 eRHF 在 95%可信区间内被 90%以上的确诊为 CMPA 的儿童耐受，是牛奶蛋白基 eHF 的合理替代选择。
ClinicalTrials.gov NCT01998074。
